15
Participants
Start Date
October 31, 2025
Primary Completion Date
October 31, 2030
Study Completion Date
October 31, 2030
Vincristine
IV Push
Doxorubicin
IV
Cyclophosphamide
IV and Maintenance PO
Ifosfamide
IV
Actinomycin
IV
Irinotecan
IV
Cabozantinib
PO
Topotecan
IV
Temozolomide
IV
Etoposide
PO
Liposomal doxorubicin
IV
NOT_YET_RECRUITING
Montefiore Medical Center, The Bronx
NOT_YET_RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
NOT_YET_RECRUITING
University of North Carolina, Chapel Hill
NOT_YET_RECRUITING
Levine Cancer Institute, Charlotte
NOT_YET_RECRUITING
Nemours Jacksonville, Jacksonville
NOT_YET_RECRUITING
University of Florida, Gainesville
NOT_YET_RECRUITING
University of Miami, Miami
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
University of Alabama at Birmingham (Children's of Alabama), Birmingham
NOT_YET_RECRUITING
Vanderbilt University Medical Center, Nashville
NOT_YET_RECRUITING
University of Kentucky, Lexington
NOT_YET_RECRUITING
Nationwide Children's Hospital, Columbus
NOT_YET_RECRUITING
Cleveland Clinic Children's, Cleveland
NOT_YET_RECRUITING
Helen DeVos Children's Hospital, Grand Rapids
NOT_YET_RECRUITING
Primary Children's Hospital, Salt Lake City
NOT_YET_RECRUITING
Phoenix Children's Hospital, Phoenix
NOT_YET_RECRUITING
Connecticut Children's Medical Center, Hartford
National Pediatric Cancer Foundation
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER